The New Medicines Group's role in advising AWMSG

Dr James Coulson BSc LLM MD FRCP ERT Chair, New Medicines Group

All Wales Medicines Strategy Group Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Thank You!


- Dr Saad Al-Ismail Chair of the New Medicines Group 2014 to June 2018
 - Chair of the Cancer Commissioning Group-ABM University Health Board,
 - Chair of the Thrombosis and Anticoagulation Committee at ABM University Health Board.
 - MDT Lead Consultant Haematologist in ABM University Health Board
 - Medical Director and lead cancer clinician for South West Wales cancer Network (2000-2011).



The New Medicines Group's role in advising AWMSG

- The role of New Medicines Group in the Health Technology Appraisal process
- How New Medicines Group operates
- Submissions to New Medicines Group: five year trends
- Future challenges






New Medicines Group (NMG)

NMG evaluates:

- 1. Written evidence from the applicant company,
- AWMSG Secretariat Assessment Report (NMG led & AWTTC led)
- 3. Views from clinical experts in the field
- 4. Views of relevant patients/carers/patient organisations.

NMG considers:

- 1. Clinical effectiveness
- 2. Cost-effectiveness



NMG makes preliminary recommendation to AWMSG

All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

10 meetings a year


NMG Membership

Voting Members (14)	Non-voting Members
 Chair Pharmacists Doctors Professional eligible to prescribe Nurse Public Health Wales representative Health Economist ABPI Cymru Wales representative Lay member Welsh Health Specialised Services Committee representative 	 Welsh Government (Chief Pharmaceutical officer) AWMSG Chair (or nominee) AWTTC Representative Medicines & Therapeutics Committees Health Economist


AWTTC Secretariat




Total number of submissions to NMG: 5 year trend



Types of submission to NMG: 5 year trend



Full submissions to NMG by therapeutic class (BNF chapter)




- Malignant disease and immunosuppression
- Nutrition and blood
- Respiratory system

Skin

Musculoskeletal and joint diseases

Obstetrics, gynaecology and urinary-tract disorders

Limited submissions to NMG by therapeutic class (BNF chapter)



- Cardiovascular
- Ear, nose and oropharynx
- Eye
- Infections
- Musculoskeletal and joint diseases
- Obstetrics, gynaecology and urinary-tract disorders
- Skin

- Endocrine system
- Gastrointestinal system
- Malignant disease and immunosuppression
- Nutrition and blood
- Respiratory system

Percentage of medicines recommended* by NMG and AWMSG



*Includes "recommended with restrictions"

Future challenges

Factor	Analysis	Deduction
Number of medicines to review at each meeting	Declining total number of submissions and increasing proportion of limited	 Increasing time for training and other quality improvement activities Virtual meetings
Classes of medicines	Increasing variety of therapeutic area	Increasing requirement for diverse clinical expert & patients groups
Recommendations to AWMSG	More details of decision requested by AWMSG – trial of decision table	Measure of effects required

Thank you

